Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

1.

Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs.

Picard J, Jacka B, Høj S, Laverdière É, Cox J, Roy É, Bruneau J.

AIDS Behav. 2020 Jan 29. doi: 10.1007/s10461-020-02800-w. [Epub ahead of print]

PMID:
31997057
2.

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.

Pincez T, Bruneau J, Berteloot L, Piekarski E, Thomas C, Marçais A, Trinquand A, Castelle M, Garcelon N, Plantaz D, Cheminant M, Moshous D, Molina TJ, Hermine O, Macintyre E, Fischer A, Blanche S, Suarez F, Neven B.

Haematologica. 2019 Dec 26. pii: haematol.2019.230276. doi: 10.3324/haematol.2019.230276. [Epub ahead of print] No abstract available.

3.

Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.

Dupuy FP, Kant S, Barbé A, Routy JP, Bruneau J, Lebouché B, Tremblay C, Pazgier M, Finzi A, Bernard NF.

mBio. 2019 Dec 17;10(6). pii: e02690-19. doi: 10.1128/mBio.02690-19.

4.

Chronic Intestinal Pseudo-Obstruction and Lymphoproliferative Syndrome as a Novel Phenotype Associated With Tetratricopeptide Repeat Domain 7A Deficiency.

El-Daher MT, Lemale J, Bruneau J, Leveau C, Guerin F, Lambert N, Diana JS, Neven B, Sepulveda FE, Coulomb-L'Hermine A, Molina T, Picard C, Fischer A, de Saint Basile G.

Front Immunol. 2019 Nov 7;10:2592. doi: 10.3389/fimmu.2019.02592. eCollection 2019.

5.

Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada.

Fortier E, Sylvestre MP, Artenie AA, Minoyan N, Jutras-Aswad D, Roy É, Grebely J, Bruneau J.

Drug Alcohol Depend. 2020 Jan 1;206:107744. doi: 10.1016/j.drugalcdep.2019.107744. Epub 2019 Nov 17.

PMID:
31785537
6.

Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.

Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J.

J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699-3. doi: 10.1016/j.jhep.2019.11.012. [Epub ahead of print]

PMID:
31785345
7.

Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.

Jacka B, Larney S, Degenhardt L, Janjua N, Høj S, Krajden M, Grebely J, Bruneau J.

Am J Public Health. 2020 Jan;110(1):45-50. doi: 10.2105/AJPH.2019.305379. Epub 2019 Nov 14.

PMID:
31725310
8.

Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.

Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J.

Clin Infect Dis. 2019 Nov 2. pii: ciz1089. doi: 10.1093/cid/ciz1089. [Epub ahead of print]

PMID:
31677262
9.

Global patterns of opioid use and dependence: harms to populations, interventions, and future action.

Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, Larney S.

Lancet. 2019 Oct 26;394(10208):1560-1579. doi: 10.1016/S0140-6736(19)32229-9. Epub 2019 Oct 23.

PMID:
31657732
10.

Strategies to reduce drug-related harm: responding to the evidence base.

Degenhardt L, Wolfe D, Hall W, Hickman M, Chang J, Bruneau J, Farrell M, Griffiths P.

Lancet. 2019 Oct 26;394(10208):1490-1493. doi: 10.1016/S0140-6736(19)32232-9. Epub 2019 Oct 23. No abstract available.

PMID:
31657727
11.

The authors respond to "Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations".

Artenie AA, Bruneau J.

CMAJ. 2019 Sep 30;191(39):E1085. doi: 10.1503/cmaj.73208. No abstract available.

PMID:
31570550
12.

Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells.

Rodriguez R, Fournier B, Cordeiro DJ, Winter S, Izawa K, Martin E, Boutboul D, Lenoir C, Fraitag S, Kracker S, Watts TH, Picard C, Bruneau J, Callebaut I, Fischer A, Neven B, Latour S.

J Exp Med. 2019 Dec 2;216(12):2800-2818. doi: 10.1084/jem.20190678. Epub 2019 Sep 19.

PMID:
31537641
13.

The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.

Kiani Z, Dupuy FP, Bruneau J, Lebouché B, Retière C, Geraghty DE, Bernard NF.

J Virol. 2019 Nov 13;93(23). pii: e01185-19. doi: 10.1128/JVI.01185-19. Print 2019 Dec 1.

PMID:
31511383
14.

Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA).

Drieux F, Ruminy P, Abdel-Sater A, Lemonnier F, Viailly PJ, Fataccioli V, Machand V, Bisig B, Letourneau A, Parrens M, Bossard C, Bruneau J, Dobay P, Veresezan L, Dupuy A, Pujals A, Robe C, Sako N, Copie-Bergman C, Delfau-Larue MH, Picquenot JM, Tilly H, Delarue R, Jardin F, de Leval L, Gaulard P; TENOMIC.

Haematologica. 2019 Sep 5. pii: haematol.2019.226647. doi: 10.3324/haematol.2019.226647. [Epub ahead of print]

15.

[Histopathological classification of chronic B-lymphoproliferative disorders].

Bontoux C, Bruneau J, Molina TJ.

Presse Med. 2019 Jul - Aug;48(7-8 Pt 1):792-806. doi: 10.1016/j.lpm.2019.07.022. Epub 2019 Aug 22. Review. French.

PMID:
31447335
16.

Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.

Jacka B, Roy É, Høj S, Minoyan N, Artenie AA, Zang G, Jutras-Aswad D, Bruneau J.

J Viral Hepat. 2019 Dec;26(12):1413-1422. doi: 10.1111/jvh.13194. Epub 2019 Sep 11.

PMID:
31433888
17.

Social participation in older women and men: differences in community activities and barriers according to region and population size in Canada.

Naud D, Généreux M, Bruneau JF, Alauzet A, Levasseur M.

BMC Public Health. 2019 Aug 16;19(1):1124. doi: 10.1186/s12889-019-7462-1.

18.

Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.

Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users.

Int J Drug Policy. 2019 Oct;72:1-10. doi: 10.1016/j.drugpo.2019.07.016. Epub 2019 Jul 23.

PMID:
31345644
19.

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study.

Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J.

Clin Infect Dis. 2019 Jul 11. pii: ciz633. doi: 10.1093/cid/ciz633. [Epub ahead of print]

PMID:
31300820
20.

HLA-F on Autologous HIV-Infected Cells Activates Primary NK Cells Expressing the Activating Killer Immunoglobulin-Like Receptor KIR3DS1.

Kiani Z, Bruneau J, Geraghty DE, Bernard NF.

J Virol. 2019 Aug 28;93(18). pii: e00933-19. doi: 10.1128/JVI.00933-19. Print 2019 Sep 15.

PMID:
31270222
21.

Inherited IL-18BP deficiency in human fulminant viral hepatitis.

Belkaya S, Michailidis E, Korol CB, Kabbani M, Cobat A, Bastard P, Lee YS, Hernandez N, Drutman S, de Jong YP, Vivier E, Bruneau J, Béziat V, Boisson B, Lorenzo-Diaz L, Boucherit S, Sebagh M, Jacquemin E, Emile JF, Abel L, Rice CM, Jouanguy E, Casanova JL.

J Exp Med. 2019 Aug 5;216(8):1777-1790. doi: 10.1084/jem.20190669. Epub 2019 Jun 18.

22.

Association between mental health service utilisation and sharing of injection material among people who inject drugs in Montreal, Canada.

Côté P, Ghabrash MF, Bruneau J, Roy É, Dubreucq S, Fortier E, Jutras-Aswad D.

Addict Behav. 2019 Sep;96:175-182. doi: 10.1016/j.addbeh.2019.05.010. Epub 2019 May 13.

PMID:
31108263
23.

Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.

Artenie AA, Minoyan N, Jacka B, Høj S, Jutras-Aswad D, Roy É, Gauvin L, Zang G, Bruneau J.

CMAJ. 2019 Apr 29;191(17):E462-E468. doi: 10.1503/cmaj.181506.

24.

Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?

Makarenko I, Artenie A, Hoj S, Minoyan N, Jacka B, Zang G, Barlett G, Jutras-Aswad D, Martel-Laferriere V, Bruneau J.

Int J Drug Policy. 2019 Oct;72:69-76. doi: 10.1016/j.drugpo.2019.04.002. Epub 2019 Apr 19.

PMID:
31010749
25.

Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs.

Høj SB, Jacka B, Minoyan N, Artenie AA, Bruneau J.

Int J Drug Policy. 2019 Oct;72:11-23. doi: 10.1016/j.drugpo.2019.04.001. Epub 2019 Apr 17.

PMID:
31003825
26.

Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.

Levy N, Bruneau JM, Le Rouzic E, Bonnard D, Le Strat F, Caravano A, Chevreuil F, Barbion J, Chasset S, Ledoussal B, Moreau F, Ruff M.

J Med Chem. 2019 May 9;62(9):4742-4754. doi: 10.1021/acs.jmedchem.9b00338. Epub 2019 Apr 26.

PMID:
30995398
27.

Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada.

Fortier E, Artenie AA, Zang G, Jutras-Aswad D, Roy É, Grebely J, Bruneau J.

Addiction. 2019 Aug;114(8):1495-1503. doi: 10.1111/add.14632. Epub 2019 May 28.

PMID:
30957310
28.

Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.

Abayasingam A, Leung P, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd A, Rodrigo C; InC3 Study Group.

Infect Genet Evol. 2019 Jul;71:36-41. doi: 10.1016/j.meegid.2019.02.032. Epub 2019 Mar 8.

PMID:
30853512
29.

Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection.

Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3) Collaborative.

Clin Infect Dis. 2020 Jan 1;70(1):123-131. doi: 10.1093/cid/ciz162.

PMID:
30816419
30.

Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.

Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, McLean E, Trooskin S, Treloar C, Grebely J.

Int J Drug Policy. 2019 Apr;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. Epub 2019 Feb 8.

PMID:
30743093
31.

Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC.

Lisovsky I, Kant S, Tremblay-McLean A, Isitman G, Kiani Z, Dupuy FP, Gilbert L, Bruneau J, Shoukry NH, Lebouché B, Bernard NF.

J Leukoc Biol. 2019 Mar;105(3):551-563. doi: 10.1002/JLB.4A0617-242RRR. Epub 2019 Jan 30.

32.

Genomic variability of within-host hepatitis C variants in acute infection.

Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative.

J Viral Hepat. 2019 Apr;26(4):476-484. doi: 10.1111/jvh.13051. Epub 2019 Jan 22.

PMID:
30578702
33.

Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation.

Parlato M, Charbit-Henrion F, Abi Nader E, Begue B, Guegan N, Bruneau J, Khater S, Macintyre E, Picard C, Frédéric RL, Le Bourhis L, Allez M, Goulet O, Cellier C, Hermine O, Cerf-Bensussan N, Malamut G.

Gastroenterology. 2019 Mar;156(4):1206-1210.e1. doi: 10.1053/j.gastro.2018.11.065. Epub 2018 Dec 15. No abstract available. Erratum in: Gastroenterology. 2019 Jun;156(8):2356.

34.

Loss of ARHGEF1 causes a human primary antibody deficiency.

Bouafia A, Lofek S, Bruneau J, Chentout L, Lamrini H, Trinquand A, Deau MC, Heurtier L, Meignin V, Picard C, Macintyre E, Alibeu O, Bras M, Molina TJ, Cavazzana M, André-Schmutz I, Durandy A, Fischer A, Oksenhendler E, Kracker S.

J Clin Invest. 2019 Mar 1;129(3):1047-1060. doi: 10.1172/JCI120572. Epub 2019 Feb 4.

35.

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.

Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°.

Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17.

PMID:
30448772
36.

The evolving drug epidemic of prescription opioid injection and its association with HCV transmission among people who inject drugs in Montréal, Canada.

Bruneau J, Arruda N, Zang G, Jutras-Aswad D, Roy É.

Addiction. 2019 Feb;114(2):366-373. doi: 10.1111/add.14487. Epub 2018 Dec 9.

PMID:
30399197
37.

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.

Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravčík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P.

Lancet Infect Dis. 2018 Dec;18(12):1397-1409. doi: 10.1016/S1473-3099(18)30469-9. Epub 2018 Oct 29.

38.

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group.

Int J Drug Policy. 2018 Dec;62:94-103. doi: 10.1016/j.drugpo.2018.10.004. Epub 2018 Oct 29.

PMID:
30384028
39.

Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.

Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group.

Int J Drug Policy. 2018 Dec;62:14-23. doi: 10.1016/j.drugpo.2018.08.013. Epub 2018 Oct 22.

PMID:
30352330
40.

Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease.

Paulin MV, Couronné L, Beguin J, Le Poder S, Delverdier M, Semin MO, Bruneau J, Cerf-Bensussan N, Malamut G, Cellier C, Benchekroun G, Tiret L, German AJ, Hermine O, Freiche V.

BMC Vet Res. 2018 Oct 11;14(1):306. doi: 10.1186/s12917-018-1635-5. Review.

41.

A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues.

Derrieux C, Trinquand A, Bruneau J, Verkarre V, Lhermitte L, Alcantara M, Villarese P, Meresse B, Sibon D, Hermine O, Brousse N, Molina T, Cellier C, Cerf-Bensussan N, Malamut G, Macintyre E.

J Mol Diagn. 2019 Jan;21(1):111-122. doi: 10.1016/j.jmoldx.2018.08.006. Epub 2018 Sep 28.

42.

Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance.

Rosenberg BR, Depla M, Freije CA, Gaucher D, Mazouz S, Boisvert M, Bédard N, Bruneau J, Rice CM, Shoukry NH.

PLoS Pathog. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290. eCollection 2018 Sep.

43.

Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Liver Int. 2019 Jan;39(1):20-30. doi: 10.1111/liv.13949. Epub 2018 Sep 22. Review.

44.

Guided by gaze: Prioritization strategy when navigating through a virtual crowd can be assessed through gaze activity.

Meerhoff LA, Bruneau J, Vu A, Olivier AH, Pettré J.

Acta Psychol (Amst). 2018 Oct;190:248-257. doi: 10.1016/j.actpsy.2018.07.009. Epub 2018 Aug 24.

PMID:
30149239
45.

Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada.

Jutras-Aswad D, Le Foll B, Bruneau J, Wild TC, Wood E, Fischer B.

Can J Psychiatry. 2019 Feb;64(2):82-87. doi: 10.1177/0706743718790955. Epub 2018 Jul 22. No abstract available.

46.

Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study.

Charbit-Henrion F, Parlato M, Hanein S, Duclaux-Loras R, Nowak J, Begue B, Rakotobe S, Bruneau J, Fourrage C, Alibeu O, Rieux-Laucat F, Lévy E, Stolzenberg MC, Mazerolles F, Latour S, Lenoir C, Fischer A, Picard C, Aloi M, Dias JA, Hariz MB, Bourrier A, Breuer C, Breton A, Bronski J, Buderus S, Cananzi M, Coopman S, Crémilleux C, Dabadie A, Dumant-Forest C, Gurkan OE, Fabre A, Fischer A, Diaz MG, Gonzalez-Lama Y, Goulet O, Guariso G, Gurcan N, Homan M, Hugot JP, Jeziorski E, Karanika E, Lachaux A, Lewindon P, Lima R, Magro F, Major J, Malamut G, Mas E, Mattyus I, Mearin LM, Melek J, Navas-Lopez VM, Paerregaard A, Pelatan C, Pigneur B, Pais IP, Rebeuh J, Romano C, Siala N, Strisciuglio C, Tempia-Caliera M, Tounian P, Turner D, Urbonas V, Willot S, Ruemmele FM, Cerf-Bensussan N.

J Crohns Colitis. 2018 Aug 29;12(9):1104-1112. doi: 10.1093/ecco-jcc/jjy068.

47.

Paediatric mastocytosis: long-term follow-up of 53 patients with whole sequencing of KIT. A prospective study.

Meni C, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Jais JP, Hadj-Rabia S, Bruneau J, Fraitag S, Hanssens K, Dubreuil P, Hermine O, Bodemer C.

Br J Dermatol. 2018 Oct;179(4):925-932. doi: 10.1111/bjd.16795. Epub 2018 Sep 9.

PMID:
29787623
48.

HLA-F on HLA-Null 721.221 Cells Activates Primary NK Cells Expressing the Activating Killer Ig-like Receptor KIR3DS1.

Kiani Z, Dupuy FP, Bruneau J, Lebouché B, Zhang CX, Jackson E, Lisovsky I, da Fonseca S, Geraghty DE, Bernard NF.

J Immunol. 2018 Jul 1;201(1):113-123. doi: 10.4049/jimmunol.1701370. Epub 2018 May 9.

49.

A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder.

El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lespérance F, Lespérance P, Ouellet-Plamondon C, Bruneau J, Jutras-Aswad D.

Int Clin Psychopharmacol. 2018 Sep;33(5):268-273. doi: 10.1097/YIC.0000000000000223.

PMID:
29738425
50.

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.

Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D.

Contemp Clin Trials. 2018 Jun;69:21-27. doi: 10.1016/j.cct.2018.04.001. Epub 2018 Apr 5.

Supplemental Content

Loading ...
Support Center